ERK/MAPK 信号传导通路在胃肠道肿瘤治疗靶向中的意义

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (7): 833-836.

ERK/MAPK 信号传导通路在胃肠道肿瘤治疗靶向中的意义

黄剑雄, 吴佩

芜湖市皖南医学院弋矶山医院普外科, 芜湖241000, 安徽

收稿日期:2009-05-13 修回日期:2009-06-21 出版日期:2009-07-26 发布日期:2020-10-30
作者简介:黄剑雄, 男, 在读研究生, 研究方向:骨肠外科。Tel:15855980505 　E-mail:pthjx119@sina.com;吴佩, 男, 主任医师, 教授, 主要从事胃肠外科研究。Tel:0553-5739343 　E-mail:wp5708@sina.com

Significance of ERK/MAPK signal transduction pathway in the targeting treatment of gastrointestinal cancer

HUANG Jian-xiong, WU Pei

Department of General Surgery, Wannan Medical College Affiliated Yijishan Hospital, Wuhu 241001, Anhui, China

Received:2009-05-13 Revised:2009-06-21 Online:2009-07-26 Published:2020-10-30

摘要/Abstract

摘要： 细胞外信号调节激酶/丝裂原活化蛋白激酶(ERK/MAPK)信号传导通路在胃肠道肿瘤的发生和发展中有着重要的作用。ERK/MAPK 信号传导通路有3 个重要分子靶:小G 蛋白Ras、Raf 激酶及其MEK1/2 和ERK1/2。目前主要有3 种抑制ERK/MAPK 信号传导通路的办法:⑴破坏靶蛋白的结构和(或)功能;⑵采用功能缺失策略;⑶破坏蛋白与蛋白之间的相互作用。这些办法可为胃肠道肿瘤的治疗提供新的思路。

关键词: 细胞外信号调节激酶/丝裂原活化蛋白激酶, 信号传导, 胃肠道肿瘤, 抑制剂, 治疗

Abstract: Extracellular signal-regulated kinase mitogen-activated protein kinase (ERK/MAPK) signaling pathway plays an important role in gastrointestinal tumorigenesis and development.ERK/MAPK signal transduction pathway has three important molecular targets:the small G protein Ras, Raf kinase andMEK1/2 and ERK1/2.At present, there are three kinds of approach which can inhibit ERK/MAPK signal transduction pathway:⑴ destroying the structure and (or) function of the target protein, ⑵adopting the deficit strategy, ⑶damaging the interaction between proteins. These approaches can provide new ideas for the treatment of gastrointestinal cancer.

Key words: ERK/MAPK, signal transduction, gastroenteric tumor, inhibitor, therapy

中图分类号:

R735

黄剑雄, 吴佩. ERK/MAPK 信号传导通路在胃肠道肿瘤治疗靶向中的意义[J]. 中国临床药理学与治疗学, 2009, 14(7): 833-836.

HUANG Jian-xiong, WU Pei. Significance of ERK/MAPK signal transduction pathway in the targeting treatment of gastrointestinal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(7): 833-836.

参考文献

[1] 马景德, 齐秀芬.MAPKs 信号通路及其与疾病关联性的研究现状 [J].临床军医杂志, 2004, 32(2):95-97.
[2] McCubrey JA, Steelman LS, Chappell WH, et al.Roles of the Raf MEK ERK pathway in cell growth, malignant transformation and drug resistance [J].Biochim Biophys Acta, 2007, 1773(8):1263-1284.
[3] Bocca C, Bozzo F, Gabriel L, et al.Conjugated linoleic acid inhibits Caco-2 cell growth via ERK-MAPK signaling pathway [J].J Nutr Biochem, 2007, 18(5):332-340.
[4] Pan J, She M, Xu Z X, et al.Farnesy ltransferase Inhibitors Induce DNA Damage via Reactive Oxygen Species in Human Cancer Cells [J].Cancer Res, 2005, 65(9):3671-3681.
[5] Ochel HJ, Eichhorn K, Gademann G.Geldanamycin:the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones [J].Cell Stress Chaperones, 2001, 6(2):105-112.
[6] Ding Q, Wang Q, Evers BM.Alterations of MAPK_activities associated with intestinal cell differentiation [J].Biochem Biophys Res Commun, 2001, 284(2):282-288.
[7] Vaculova A, Hofmanova J, Soucek K, et al.Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells [J].FEBS Lett, 2006, 580(28 29):6565-6569.
[8] Sebolt-Leopold JS, Dudley DT, Herrera R, et al.Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo [J].Nat Med, 1999, 5(7):810-816.
[9] Rinehart J, Adjei AA, LoRusso PM, et al.Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer [J].J Clin Oncol, 2004, 22 (22):4456-4462.
[10] Mody N, Leitch J, Armstrong C, et al.Effects of MAP kinase cascade inhibitors on the MKK5 ERK5 pathway [J].FEBS Lett, 2001, 502(1 2):21-24.
[11] Sakuma T, Kijima H, Nishi M, et al.An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer [J].Tokai J Exp Clin Med, 2004, 29(2):35-42.
[12] Viti F, GiovannoniL, Neri D.Recombinant antibodies for the selective targeting of tumor neovasculature [J].Curr Opin Drug Discov Devel, 2002, 5(2):204-213.
[13] Cacev T, Radosevic S, Spaventi R, et al.NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer [J].Gut, 2005, 54(8):1129-1135.
[14] Holen T, Moe S E, S rb J G, et al.Tolerated wobble mutations in siRNAs decrease specificity, but can enhance activity in vivo [J].Nucleic Acids Res, 2005, 33(15): 4704-4710.
[15] Kelemen BR, Hsiao K, Goueli SA.Selective in Vivo Inhibition of Mitogen-activated Protein Kinase Activation Using Cell-permeable Peptides [J].Biol Chem, 2002, 277 (10):8741-8748.
[16] Eves EM, Shapiro P, Naik K, et al.Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint [J].Mol Cell, 2006, 23(4):561-574.